一、临床肿瘤杂志 (2024年第74卷第1期)

January/February 2024 - Volume 74 - Issue 1 (2024年1/2月第74卷第1期)
https://acsjournals.onlinelibrary.wiley.com/toc/15424863/2024/74/1

本期无药学相关内容

二、柳叶刀 (2024年第403卷第10425-10428期)

（一）03 February 2024 - Volume 403 - Issue 10425 (2024年2月3日第403卷第10425期)
https://www.thelancet.com/journals/lancet/issue/vol403no10425/PIIS0140-6736(24)X0005-7

COMMENT（评论）
1. 伤寒结合疫苗提供的长期保护：迈向消除伤寒的一步？
(Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?)
作者：Birkneh Tilahun Tadesse* (International Vaccine Institute, SNU Research Park, Korea; Department of Gobal Public Health, Karolinska Institutet, Stockholm, SwedenCenter for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Ethiopia)

WORLD REPORT（世界报道）
2. 疟疾疫苗开始常规接种
(Routine malaria vaccinations begin)
作者：Paul Adepoju

（二）10 February 2024 - Volume 403 - Issue 10426 (2024年2月10日第403卷第10426期)
https://www.thelancet.com/journals/lancet/issue/vol403no10426/PIIS0140-6736(24)X0006-9

COMMENT（评论）
1. 获取COVID-19疫苗接种和COVID-19相关的住院和死亡率
(Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality)
作者：Martin C Gulliford* (School of Life Course and Population Sciences, King's College London, UK)

CORRESPONDENCE（通信）
2. R21/Matrix-M疫苗：优化供应，发挥最大作用
(R21/Matrix-M vaccine: optimising supply, maximising impact)
作者：Chukwudi A Nnaji* (Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, South African; Medical Research Council, Cape Town, South AfricaTechnical Department, Malaria Consortium, UK)

ARTICLES（文章）
3. 疟疾候选疫苗 R21/Matrix-M 在非洲儿童中的安全性和有效性：一项多中心、双盲、随机、3期试验
(Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial)
作者：Mehreen S Datoo, Adrian V S Hill* (Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, UK)
4. 疫苗接种不足和重症COVID-19结局：针对英格兰、北爱尔兰、苏格兰和威尔士国家队列研究的Meta分析
(Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales)
作者：The HDR UK COALESCE Consortium

（三）17 February 2024 - Volume 403 - Issue 10427 (2024年2月17日第403卷第10427期)
https://www.thelancet.com/journals/lancet/issue/vol403no10427/PIIS0140-6736(24)X0007-0

COMMENT（评论）
1. 个体化新抗原癌症疫苗疗法
(Individualised neoantigen cancer vaccine therapy)
作者：Mizue Terai, Takami Sato* (Department of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, USA)
2. 一种治疗罕见疾病的新药：治疗CHAPLE病的pozelimab
(A new drug for rare diseases: pozelimab for CHAPLE disease)
作者：Alexandre Belot* (Centre International de Recherche en Infectiologie, France)

CORRESPONDENCE（通信）
3. 司库奇尤单抗治疗化脓性汗腺炎：问题仍然存在
(Secukinumab treatment of hidradenitis suppurativa: questions remain)
作者：Julia-Tatjana Maul* (Department of Dermatology and Venereology, University Hospital of Zürich, 8091 Zürich, SwitzerlandFaculty of Medicine, University of Zürich, Switzerland)
4. 司库奇尤单抗治疗化脓性汗腺炎：问题仍然存在
(Secukinumab treatment of hidradenitis suppurativa: questions remain)
作者：Michioki Endo* (Mitoyo General Hospital, Japan)
5. 司库奇尤单抗治疗化脓性汗腺炎：问题仍然存在——作者回复
(Secukinumab treatment of hidradenitis suppurativa: questions remain– Authors' reply)
作者：Alexa B Kimball* (Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, USA)

ARTICLES（文章）
6. 黑色素瘤切除术后的个体化新抗原治疗mRNA-4157 (V940)联合帕博利珠单抗与帕博利珠单抗单药治疗的比较(KEYNOTE-942)：一项随机2b期研究
(Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study)
作者：Jeffrey S Weber* (Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, USA)
7. 评估pozelimab在伴补体过度激活、血管病性血栓形成和蛋白丢失性肠病的CD55缺乏症患者中的疗效和安全性：一项开放标签2期和3期研究
(Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study)
作者：Ahmet Ozen, Olivier A Harari* (Department of Pediatrics, Division of Allergy and Immunology, Marmara University, School of Medicine, Türkiye; Regeneron Pharmaceuticals, USA)

（四）24 February 2024 - Volume 403 - Issue 10428 (2024年2月24日第403卷第10428期)
https://www.thelancet.com/journals/lancet/issue/vol403no10428/PIIS0140-6736(24)X0008-2

COMMENT（评论）
1. Gepotidacin，一种治疗单纯性尿路感染的新一级抗生素
(Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection)
作者：Ased S M Ali* (Department of Urology, Mid Yorkshire Teaching NHS Trust, UK)

ARTICLES（文章）
2. 口服gepotidacin与呋喃妥因治疗单纯性尿路感染的比较(EAGLE-2和EAGLE-3)：两项随机、对照、双盲、双模拟、3期非劣效性试验
(Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials)
作者：Florian Wagenlehner* (Wagenlehner, Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Germany)

三、新英格兰医学杂志 (2024年2月第390卷第5-9期)

（一）1 February 2024 - Volume 390 - No 5 (2024年2月1日第390卷第5期)
https://www.nejm.org/toc/nejm/390/5

ORIGINAL ARTICLES（原创文章）
1. 用于儿童和成人的四价布坦-登革热减毒活疫苗
(Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults)
作者：Esper G. Kallás, Fernanda Castro Boulos* (Instituto Butantan, Brazil)
2. N-乙酰基-l-亮氨酸在C型尼曼-匹克病中的试验
(Trial of N-Acetyl-l-Leucine in Niemann–Pick Disease Type C)
作者：Tatiana Bremova-Ertl*, Michael Strupp* (Department of Neurology, University Hospital Bern, Switzerland; Department of Neurology, Hospital of the Ludwig Maximilians University Munich, Germany)

EDITORIAL（社论）
3. 三种登革热疫苗——现在该怎么办？
(Three Dengue Vaccines — What Now?)
作者：Scott B. Halstead (Westwood, MA. Dr. Halstead is the founding director (retired) of the Pediatric Dengue Vaccine Initiative, International Vaccine Institute, South Korea)
4. N-乙酰-L-亮氨酸与神经退行性疾病
(N-Acetyl-l-Leucine and Neurodegenerative Disease)
作者：Cynthia J. Tifft (Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, USA)

CORRESPONDENCE（通信）
5. Volanesorsen预防高甘油三酯血症中的急性胰腺炎
(Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia)
作者：Veronica J. Alexander (Ionis Pharmaceuticals, USA)
6. 奥希替尼联合化疗治疗 EGFR突变的NSCLC
(Osimertinib with Chemotherapy in EGFR-Mutated NSCLC)
7. 沙利度胺治疗小肠血管发育不良出血
(Thalidomide for Bleeding from Small-Intestinal Angiodysplasia)
8. 万古霉素和头孢唑林作为手术预防的试验
(Trial of Vancomycin and Cefazolin as Surgical Prophylaxis)

（二）08 February 2024 - Volume 390 - No 6 (2024年2月8日第390卷第6期)
https://www.nejm.org/toc/nejm/390/6

ORIGINAL ARTICLES（原创文章）
1. Resmetirom治疗NASH伴肝纤维化的3期随机对照试验
(A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis)
作者：Stephen A. Harrison* (University of Oxford, UK)
2. 用于治疗斑块状银屑病的口服白细胞介素-23受体拮抗剂肽
(An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis)
作者：Robert Bissonnette* (Innovaderm Research, Canada)

EDITORIAL（社论）
3. 用于治疗NASH的选择性甲状腺激素受体β激动剂
(Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH)
作者：Kenneth Cusi (Division of Endocrinology, Diabetes, and Metabolism, University of Florida, USA)

CORRESPONDENCE（通信）
4. SGLT2 抑制剂和假阳性毒理学试验
(SGLT2 Inhibitors and False Positive Toxicology Tests)
作者：Aaron L. Schwartz (Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, USA)
5. 静脉注射左旋甲状腺素治疗不稳定的脑死亡心脏供者
(Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors)
6. 婴儿III、IV或V级膀胱输尿管反流的抗生素预防
(Antibiotic Prophylaxis for Grade III, IV, or V Vesicoureteral Reflux in Infants)
7. 埃万妥单抗联合化疗治疗非小细胞肺癌有静脉血栓栓塞的风险
(VTE with Amivantamab plus Chemotherapy in NSCLC)

（三）15 February 2024 - Volume 390 - No 7 (2024年2月15日第390卷第7期)
https://www.nejm.org/toc/nejm/390/7

ORIGINAL ARTICLES（原创文章）
1. 通过Frexalimab抑制CD40L治疗多发性硬化症
(Inhibition of CD40L with Frexalimab in Multiple Sclerosis)
作者：Patrick Vermersch* (Clinique de Neurologie, Hôpital Roger Salengro, Centre Hospitalier Universitaire de Lille, France)
2. 用于戒烟的电子尼古丁输送系统
(Electronic Nicotine-Delivery Systems for Smoking Cessation)
作者：Reto Auer* (Institute of Primary Health Care (BIHAM), University of Bern, Switzerland)
3. 头孢吡肟-他尼硼巴坦治疗复杂性尿路感染
(Cefepime–Taniborbactam in Complicated Urinary Tract Infection)
作者：Florian M. Wagenlehner¹; Leanne B. Gasink²; Paul C. McGovern³* (1.Justus Liebig University, Germany; 2.LBG Consulting, USA; 3.Venatorx Pharmaceuticals, USA)
4. 大剂量ERT、利妥昔单抗和早期HSCT治疗患有Wolman病的婴儿
(High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman’s Disease)
作者：Siawosh K. Eskandari¹; Elisabeth G.M. Revenich²; Peter M. van Hasselt³*; Caroline A. Lindemans⁴*; Charlotte M.A. Lubout⁵* (1.Department of Metabolic Diseases, Beatrix Children’s Hospital, the Netherlands; 2.Department of Stem Cell Transplantation, Princess Máxima Center for Pediatric Oncology, the Netherlands; 3.Department of Metabolic Diseases, Wilhemina Children’s Hospital, the Netherlands; 4.University Medical Center (UMC) Groningen, Groningen, the Division of Pediatrics, the Netherlands; 5.Department of Metabolic Diseases, Beatrix Children’s Hospital, UMC Groningen, University of Groningen, the Netherlands)

（四）22 February 2024 - Volume 390 - No 8 (2024年2月22日第390卷第8期)
https://www.nejm.org/toc/nejm/390/8

Perspective（透视）
1. 新型抗肥胖药物直面消费者平台——担忧和潜在机遇
(Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities)
作者：Ilya Golovaty (VA Puget Sound Health Care System (I.G., S.H.), and the Division of General Internal Medicine, University of Washington, USA)

ORIGINAL ARTICLES（原创文章）
2. 灌注成像选择下替奈普酶在4.5 ~ 24小时卒中的治疗
(Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection)
作者：Gregory W. Albers* (Stanford Stroke Center, Department of Neurology and Neurological Sciences, Stanford University, USA)
3. Rusfertide，一种铁调素模拟物，用于控制真性红细胞增多症患者的红细胞增多症
(Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera)
作者：Marina Kremyanskaya* (Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, USA)

EDITORIAL（社论）
4. 替奈普酶治疗中风——打开了一扇窗？
(Tenecteplase for Stroke — Opening the Window?)
作者：Dana Leifer (Department of Neurology, Weill Cornell Medical College, USA)

CORRESPONDENCE（通信）
5. 司美格鲁肽与心血管结局
(Semaglutide and Cardiovascular Outcomes)
6. 吸入阿米卡星预防呼吸机相关性肺炎
(Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia)

CORRECTION（校正）
7. BNT162b2和mRNA-1273疫苗对Covid-19的预防和抑制作用
(Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines)

（五）29 February 2024 - Volume 390 - No 9 (2024年2月29日第390卷第9期)
https://www.nejm.org/toc/nejm/390/9

ORIGINAL ARTICLES（原创文章）
1. Seladelpar治疗原发性胆汁性胆管炎的3期试验
(A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis)
作者：Gideon M. Hirschfield* (Toronto General Hospital, Toronto Centre for Liver Disease, Canada)
2. Elafibranor在原发性胆汁性胆管炎中的疗效和安全性
(Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis)
作者：Kris V. Kowdley* (Liver Institute Northwest, Italy )

EDITORIAL（社论）
3. PPAR激动剂治疗原发性胆汁性胆管炎
(PPAR Agonists in Primary Biliary Cholangitis)
作者：Bernd Schnabl (Department of Medicine, University of California, USA)

CORRESPONDENCE（通信）
4. Gantenerumab治疗早期阿尔茨海默病
(Gantenerumab in Early Alzheimer’s Disease)

四、美国医学会杂志 (2024年2月第331卷第5-8期)

（一）6 February 2024 -Volume 331 - No.5 (2024年2月6日第331卷第5期)
https://jamanetwork.com/journals/jama/issue/331/5

Original Investigation（原始调查）
1. 妊娠期接种 COVID-19 疫苗后的新生儿结局
(Neonatal Outcomes After COVID-19 Vaccination in Pregnancy)
作者：Mikael Norman (Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Sweden)
2. 二价mRNA COVID-19疫苗预防5至17岁儿童和青少年SARS-CoV-2感染的有效性
(Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years)
作者：Leora R. Feldstein (Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, USA)

Medical News in Brief（医学新闻简讯）
3. 女性性行为后使用抗生素可能无法预防性传播感染
(Antibiotic Use After Sex Might Not Prevent STIs Among Women)
作者：Emily Harris

（二）13 February 2024 -Volume 331 - No.6 (2024年2月13日第331卷第6期)
https://jamanetwork.com/journals/jama/issue/331/6

Original Investigation（原始调查）
1. 在布基纳法索大规模分发阿奇霉素以预防儿童死亡：CHAT 随机临床试验
(Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso:The CHAT Randomized Clinical Trial)
作者：Catherine E. Oldenburg (Francis I. Proctor Foundation, University of California, USA)
2. 老年女性透析依赖患者使用地诺单抗后出现的严重低钙血症
(Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients)
作者：Steven T. Bird (Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, FDA, USA)

Research Letter（研究信函）
3. 2021年物质使用治疗机构中的长效丁丙诺啡注射供应情况
(Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021)
作者：Nitin Vidyasagar (Pritzker School of Medicine, The University of Chicago, USA)

Editorial（社论）
4. 阿奇霉素预防非洲儿童死亡：更多数据，更多问题
(Azithromycin for Prevention of Mortality in African Children: More Data, More Questions)
作者：Chandy C. John (Indiana University School of Medicine, USA)

Medical News in Brief（医学新闻简讯）
5. FDA批准首个从加拿大进口处方药物的州计划
(FDA Approves First State Program to Import Rx Drugs From Canada)
作者：Emily Harris
6. 司美格鲁肽与降低自杀念头风险有关
(Semaglutide Linked With Lower Risk of Suicidal Thoughts)
作者：Emily Harris
7. 阿杜那单抗联合聚焦脑超声疗效更好
(Aducanumab Combined With Focused Brain Ultrasound More Effective)
作者：Emily Harris

JAMA Patient Page（JAMA患者页面）
8. 治疗眼睛过敏的非处方药
(Nonprescription Medications for Eye Allergies)
作者：Sarah E. Vordenberg (Clinical Pharmacy, University of Michigan College of Pharmacy, USA)

Comment & Response（评论与回应）
9. Gefapixant治疗慢性咳嗽
(Gefapixant for Chronic Cough)
作者：Richard D. Turner (School of Medicine and Dentistry, Griffith University, Australia)
10. Gefapixant治疗慢性咳嗽——回复
(Gefapixant for Chronic Cough)
作者：Elena Kum (Department of Health Research Methods, Evidence, and Impact, McMaster University, Canada)
11. 高血压和心血管疾病风险的药物治疗
(Pharmacologic Treatment for High BP and Risk of CVD)
作者：Jose-Alberto Palma (Department of Neurology, NYU School of Medicine, USA)
12. 高血压和心血管疾病风险的药物治疗——回复
(Pharmacologic Treatment for High BP and Risk of CVD)
作者：Stephen P. Juraschek (Department of Medicine, Beth Israel Deaconess Medical Center, USA)

（三）20 February 2024 -Volume 331 - No.7 (2024年2月20日第331卷第7期)
https://jamanetwork.com/journals/jama/issue/331/7

Original Investigation（原始调查）
1. 阿哌沙班预防心房性心脏病患者隐源性卒中后复发：ARCADIA随机临床试验
(Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy:The ARCADIA Randomized Clinical Trial)
作者：Hooman Kamel (Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, USA)

Editorial（社论）
2. 隐源性卒中中心房性心脏病的抗凝治疗
(Anticoagulation for Atrial Cardiopathy in Cryptogenic Stroke)
作者：Gregory M. Marcus (Division of Cardiology, University of California, USA)

Medical News & Perspectives（医学新闻与观点）
3. Paxlovid 有效但未得到充分利用——以下是关于反弹等的最新研究
(Paxlovid Is Effective but Underused—Here’s What the Latest Research Says About Rebound and More)
作者：Rita Rubin

Medical News in Brief（医学新闻简讯）
4. 妊娠期丁丙诺啡治疗可能比美沙酮更安全
(Buprenorphine Treatment May Be Safer Than Methadone During Pregnancy)
作者：Emily Harris

Comment & Response（评论与回应）
5. 妊娠糖尿病的二甲双胍早期治疗
(Early Metformin Treatment for Gestational Diabetes)
作者：Jiahao Meng (Department of Orthopaedics, Xiangya Hospital Central South University, China)
6. 妊娠糖尿病的二甲双胍早期治疗
(Early Metformin Treatment for Gestational Diabetes)
作者：Yeojin Park (University of Ulsan College of Medicine, Ulsan University Hospital, South Korea)
7. 妊娠糖尿病的二甲双胍早期治疗——回复
(Early Metformin Treatment for Gestational Diabetes—Reply)
作者：Fidelma Dunne (School of Medicine University of Galway, Galway University Hospital, Ireland)

（四）27 February 2024 -Volume 331 - No.8 (2024年2月27日第331卷第8期)
https://jamanetwork.com/journals/jama/currentissue

Medical News in Brief（医学新闻简讯）
1. 非洲首个常规疟疾疫苗接种运动开始
(Africa’s First Routine Malaria Vaccination Campaign Begins)
作者：Emily Harris

Comment & Response（评论与回应）
2. 兰地洛尔在感染性休克和器官衰竭患者中的应用
(Use of Landiolol for Patients With Septic Shock and Organ Failure)
作者：Konstantinos Mantzarlis (Department of Critical Care, University Hospital of Larissa, Greece)
3. 兰地洛尔在感染性休克和器官衰竭患者中的应用——回复
(Use of Landiolol for Patients With Septic Shock and Organ Failure—Reply)
作者：Tony Whitehouse (University Hospitals of Birmingham, NHS Foundation Trust, UK)
4. 头孢吡肟与哌拉西林-他唑巴坦治疗住院成人急性感染的比较
(Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults)
作者：Rishi Chanderraj (Department of Internal Medicine, University of Michigan Medical School, USA)
5. 头孢吡肟与哌拉西林-他唑巴坦治疗住院成人急性感染的比较
(Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults)
作者：Tanguy Dequidt (Department of Infectious Diseases, Guadeloupe University Hospital, France)
6. 头孢吡肟与哌拉西林-他唑巴坦治疗住院成人急性感染的比较
(Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults)
作者：Dayu Chen (Department of Pharmacy, Nanjing Drum Tower Hospital, China)
7. 头孢吡肟与哌拉西林-他唑巴坦治疗住院成人急性感染的比较——回复
(Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults—Reply)
作者：Edward T. Qian (Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, USA)

五、自然：药物发现综述

February 2024 - Volume 23 - Issue 2 (2024年2月第23卷第2期)
https://www.nature.com/nrd/volumes/23/issues/2

NEWS IN BRIEF（简讯）
1. 用于精神分裂症的毒蕈碱受体调节剂吸引了数十亿美元的关注
(Muscarinic receptor modulators for schizophrenia attract multibillion-dollar attention)
作者：Asher Mullard

BIOBUSINESS BRIEFS（生物商业简报）
2. 肌萎缩侧索硬化的药物开发趋势
(Trends in drug development for amyotrophic lateral sclerosis)
作者：Selma Kraft* (US FDA, USA)

RESEARCH HIGHLIGHT（研究亮点）
3. 治疗芬太尼过量的单克隆抗体
(Monoclonal antibody to treat fentanyl overdose)
作者：Sarah Crunkhorn
4. 可解释的深度学习发现新型抗生素
(Explainable deep learning discovers novel antibiotic)
作者：Sarah Crunkhorn

Review Article（评论文章）
5. 细胞外靶向蛋白降解：一种新兴的药物发现模式
(Extracellular targeted protein degradation: an emerging modality for drug discovery)
作者：James A. Wells* (Department of Pharmaceutical Chemistry, University of California San Francisco, USA)

Perspective（透视）
6. 将QSAR建模和深度学习整合到药物发现中：深度QSAR的出现
(Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR)
作者：Alexander Tropsha* (University of North Carolina at Chapel Hill, USA)

六、自然：免疫学综述 (2024年2月第24卷第2期)

February 2024 - Volume 24 - Issue 2 (2024年2月第24卷第2期)
https://www.nature.com/nri/volumes/24/issues/2

Comment（评论）
1. 使用卡介苗预防COVID-19：当现实未能达到预期时
(Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation)
作者：Laure F. Pittet (Department of Paediatrics, The University of Melbourne, Australia)

七、柳叶刀：呼吸医学 (2024年第12卷第2期)

February 2024 - Volume 12 - Number 2 (2024年第12卷第2期)
https://www.thelancet.com/journals/lanres/issue/vol12no2/PIIS2213-2600(24)X0002-8

CORRESPONDENCE（通信）
1. 贝达喹啉、普瑞玛尼和利奈唑胺联合或不联合莫西沙星治疗结核病
(Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis)
作者：Sarah M Labuda, Neela D Goswami* (US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, USA; US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, USA)

ARTICLES（文章）
2. 耐利福平的肺结核病患者短期口服方案（TB-PRACTECAL）：一项开放标签、随机、对照、2B-3 期、多臂、多中心、非劣效性试验
(Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial)
作者：Bern-Thomas Nyang'wa* (Nyang’wa, Public Health Department OCA, Médecins Sans Frontières, Netherlands)

八、英国医学期刊 (2024年2月第384卷第8415-8418期)

（一）03 February 2024 - Volume 38 - Issue 8415 (2024年2月3日第384卷第8415期)
https://www.bmj.com/content/384/8415

Research（研究）
1. GLP-1受体激动剂对2型糖尿病血糖控制、体重和血脂水平的有效性比较：系统评价和网状Meta分析
(Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis)
作者：Haiqiang Yao, Jin-Yi Wan* (School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, China)

Practice（实践）
2. 他汀类药物
(Statins)
作者：Spoorthy Kulkarni, Michalis Kostapanos* (Clinical Pharmacology Unit, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, UK)

（二）10 February 2024 - Volume 384 - Issue 8416 (2024年2月10日第384卷第8416期)
https://www.bmj.com/content/384/8416

News（新闻）
1. NICE 表示，脓毒症风险最高的患者应立即使用抗生素
(Target patients at highest risk of sepsis for immediate antibiotics, says NICE)
作者：Elisabeth Mahase

Editorials（社论）
2. 对新型减肥药物的公共卫生观点
(Public health perspective on new weight loss medications)
作者：Oliver T Mytton (UCL Great Ormond Street Institute of Child Health, UK)

Letters（信件）
3. 限制抗抑郁药的使用：围绝经期妇女可能受益于 HRT
(Curb antidepressant use: perimenopausal women may benefit from HRT)
作者：Sarah Glynne (Portland Hospital, UK)

（三）17 February 2024 - Volume 384 - Issue 8417 (2024年2月17日第384卷第8417期)
https://www.bmj.com/content/384/8417

Practice（实践）
1. 噻嗪类利尿剂
(Thiazide diuretics)
作者：Steven D Anisman (North Country Cardiology, USA)

（四）24 February 2024 - Volume 384 - Issue 8418 (2024年2月24日第384卷第8418期)
https://www.bmj.com/content/384/8418

News（新闻）
1. 感染专家呼吁更明确地开具氟喹诺酮类药物
(Infection specialists call for more clarity on prescribing fluoroquinolones)
作者：Ingrid Torjesen

Research（研究）
2. 幼儿接种流感疫苗的最佳时机:基于人群的队列研究
(Optimal timing of influenza vaccination in young children: population based cohort study)
作者：Christopher M Worsham, Anupam B Jena* (Department of Health Care Policy, Harvard Medical School, USA)

Opinion（意见）
3. RSV疫苗接种推广和电子尼古丁输送系统
(RSV vaccination roll-outs and electronic nicotine delivery systems)
作者：Tom Nolan

九、自然：医学 (2024年2月第30卷第2期)

February 2024 - Volume 30 - Issue 2 (2024年2月第30卷第2期)
https://www.nature.com/nm/volumes/30/issues/2

News & Views（新闻和观点）
1. 一种治疗创伤性脑损伤的古老迷幻药
(An ancient psychedelic for traumatic brain injury)
作者：David L. Brody* (Department of Neurology, Military Traumatic Brain Injury Initiative, Uniformed Services University of the Health Sciences, USA)

Article（文章）
2. 镁-伊博格碱治疗创伤性脑损伤的退伍军人
(Magnesium–ibogaine therapy in veterans with traumatic brain injuries)
作者： Kirsten N. Cherian, Jackob N. Keynan, Ian H. Kratter*, Nolan R. Williams* (Brain Stimulation Lab, Department of Psychiatry & Behavioral Sciences, Stanford School of Medicine, USA)
3. 烟酸的一种末端代谢物会促进血管炎症并增加心血管疾病风险
(A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk)
作者：Marc Ferrell, Stanley L. Hazen* (Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, USA)
4. osocimab对接受血液透析的肾衰竭患者的抗凝治疗：一项随机2期试验
(Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial)
作者：Jeffrey I. Weitz* (Thrombosis and Atherosclerosis Research Institute and McMaster University, Canada)
5. 瑞普替尼与舒尼替尼在治疗胃肠道间质瘤中的比较：3期INTRIGUE试验的ctDNA生物标志物分析
(Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial)
作者：Michael C. Heinrich, Sebastian Bauer* (Division of Hematology/Oncology, Portland VA Health Care System, USA; Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany)
6. 胃癌和胃食管结合部腺癌的阿替利珠单抗联合化疗新辅助治疗：2期PANDA试验
(Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial)
作者：Yara L. Verschoor, Myriam Chalabi* (Department of Gastrointestinal Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, the Netherlands)
7. 靶向淋巴结的mKRAS 特异性两亲疫苗治疗胰腺癌和结直肠癌：1 期 AMPLIFY-201 试验
(Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial)
作者：Shubham Pant*, Eileen M. O’Reilly* (The University of Texas MD Anderson Cancer Center, USA; Memorial Sloan Kettering Cancer Center, USA)
8. Belantamab mafodotin、泊马度胺和地塞米松治疗难治性多发性骨髓瘤：一项1/2期试验
(Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial)
作者：Suzanne Trudel* (Princess Margaret Cancer Centre, University Health Network, Canada)
9. 局部晚期胃癌或胃食管交界处癌围手术期的特瑞普利单抗和化疗治疗：一项随机2期试验
(Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial)
作者：Shu-Qiang Yuan1, Run-Cong Nie¹, Ying Jin², Cheng-Cai Liang¹, Yuan-Fang Li¹, Zhi-Wei Zhou¹*, Rui-Hua Xu²*, Feng Wang²* (1.Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, China; 2.Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, China)

Author Correction（作者跟正）
10. 作者更正：局部晚期胃癌或胃食管交界处癌围手术期的特瑞普利单抗和化疗治疗：一项随机2期试验
(Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial)
作者：Shu-Qiang Yuan¹, Run-Cong Nie¹, Ying Jin², Cheng-Cai Liang¹, Yuan-Fang Li¹, Zhi-Wei Zhou¹*, Rui-Hua Xu²*, Feng Wang²* (1.Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, China; 2.Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, China)

Publisher Correction（出版商更正）
11. 出版商更正：Pepinemab抗体阻断SEMA4D治疗早期亨廷顿病：一项随机、安慰剂对照的2期试验
(Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial)
作者：Andrew Feigin, Maurice Zauderer* (New York University Langone Health and The Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, USA; Vaccinex, Inc., USA)
12. 出版商更正：纳武利尤单抗在切除的IIB/C期黑色素瘤中的辅助治疗:来自随机3期CheckMate 76K试验的主要结果
(Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial)
作者：John M. Kirkwood* (UPMC Hillman Cancer Center, USA)

十、世界精神病学 (2024年第23卷第1期)

（一）2024 - Volume 23 - Issue 1 (2024年第23卷第1期)
https://onlinelibrary.wiley.com/toc/20515545/2024/23/1

Insight（见解）
1. 在用精神药物治疗女性时，需要考虑性别差异
(Sex differences need to be considered when treating women with psychotropic drugs)
作者：Iris E. Sommer (Department of Psychiatry, University Medical Center Groningen, The Netherlands)

Letter to the Editor（致编辑的信）
2. 抑郁症序贯治疗后的累积缓解率：STAR*D试验数据的再评价
(Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data)
作者：Hitoshi Sakurai (Department of Neuropsychiatry, Kyorin University Faculty of Medicine, Japan)
3. 当与迷幻药联用时，心理治疗应如何进行？
(How should psychotherapy proceed when adjoined with psychedelics?)
作者：Marc J. Weintraub (Department of Psychiatry and Biobehavioral Sciences, University of California, and Semel Institute for Neuroscience and Behavior, USA)